Now Available for Use
This medicine has provisional approval in Australia to treat COVID-19 in adults, 18 years and older, who do not need additional oxygen therapy, but who are at increased risk of progressing to need hospitalisation or of death. This approval has been granted on the basis of short term efficacy and safety data. Evidence of longer term efficacy and safety from ongoing trials continues to be gathered and submitted to the Regulatory authority for assessment.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may experience to your doctor, or directly at www.tga.gov.au/reporting-problems
Product Expiration Date
The Product Expiration Date is stated on the product packaging, both on the carton and on the individual blister cards.
COVID-19 is caused by a virus called coronavirus, SARS-CoV-2. You can get COVID-19 through close contact with another person who has the virus.
Symptoms of COVID-19 can range from very mild (including some with no reported symptoms) to severe, including illness resulting in death. In certain patients, COVID-19 may also cause some of your other medical conditions to become worse.
Older people and people of all ages with severe, long-lasting (chronic) medical conditions like heart disease, lung disease, and diabetes, for example, seem to be at higher risk of being hospitalised for COVID-19.
The symptoms of COVID-19 can include fever, cough, and shortness of breath, which may appear 2 to 14 days after exposure. Serious illness, including breathing problems, can occur and may cause your other medical conditions to become worse.
You can find the full list of potential COVID-19 symptoms from the Australian Government here.
Australia Government, Dept of Health, Covid-19 Disease, Symptoms & Variants. https://www.health.gov.au/health-alerts/covid-19/symptoms-and-variants.
PAXLOVID is used to treat COVID-19 in people over 18 years who are at increased risk of progressing to increased risk of hospitalisation or death.
PAXLOVID contains the active ingredients nirmatrelvir and ritonavir.
PAXLOVID is used in Australia to treat COVID‑19 in adult patients with positive results of direct SARS‑CoV‑2 viral testing, and who are at increased risk of progression to hospitalisation or death.
You should speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about taking PAXLOVID.
Learn how and when to take this medicine.
Learn about important possible side effects.
PAXLOVID must be prescribed by a licensed healthcare professional and supplied by a Government-approved pharmacy or medical facility.
Authentic PAXLOVID, from Pfizer Australia Pty Ltd., will include the Pfizer name on the label and will be packaged in 5 aluminum push-through blister cards. Individual doses are not for sale. PAXLOVID will be packaged in a rectangular carton. The carton has a colourless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over the tablet, and these repeating features are seen in a contrasting matte finish.
PAXLOVID consists of tablets for a 5-day oral treatment regimen, with morning and evening doses.
Front: 3CL | Back: PFE
Front: NK | Back: No text
Pfizer is committed to patient safety and ensuring that people have accurate information about PAXLOVID, including how it is accessed and administered. We are actively monitoring for offers of illegitimate PAXLOVID to protect patients from products that might be dangerous and lead to serious and life-threatening harm.
If you suspect the product you have received may be counterfeit, contact us at 1800 675 229 or visit www.pfizermedicalinformation.com.au
For more information
This site is intended only for Australian residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.